CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Viatris Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Viatris Inc
1000 Mylan Boulevard
Phone: (724) 514-1800p:724 514-1800 CANONSBURG, PA  15317  United States Ticker: VTRSVTRS
Business Summary
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYesYes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman Emeritus of the Board Robert J.Coury 63 12/15/2023 11/16/2020
Chief Executive Officer, Director Scott A.Smith 62 4/1/2023 12/29/2022
Lead Independent Vice Chairman of the Board Mark W.Parrish 68 11/16/2020 11/16/2020
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ROTTAPHARM LIMITED DAMASTOWN INDUSTRIAL PARK MULHUDDART IE
UPJOHN MANUFACTURING IRELAND UNLIMITED COMPANY LITTLE ISLAND T45 F627 IE
UPJOHN UK 2 LTD. RAMSGATE ROAD SANDWICH UK
24 additional Subsidiary records available in full report.

Business Names
Business Name
Abbex AB
Acton Pharmaceuticals, Inc.
Agila Australasia Pty Ltd
291 additional Business Names available in full report.

General Information
Number of Employees: 38,000 (As of 12/31/2023)
Outstanding Shares: 1,193,592,902 (As of 10/11/2024)
Shareholders: 103,200
Stock Exchange: NASD
Federal Tax Id: 834364296
Fax Number: (302) 655-5049
Email Address: investor_relations@mylan.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025